Comparative Pharmacology
Head-to-head clinical analysis: DIGOXIN PEDIATRIC versus LANOXICAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIGOXIN PEDIATRIC versus LANOXICAPS.
DIGOXIN PEDIATRIC vs LANOXICAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium ATPase, increasing intracellular sodium, which promotes calcium influx via sodium-calcium exchanger, enhancing cardiac contractility. Also increases vagal tone, slowing AV conduction.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
For pediatric patients, digoxin pediatric dosing is weight-based; no standard adult dose. Typical pediatric loading dose: 10-12 mcg/kg orally divided every 6-8 hours, with maintenance: 5-10 mcg/kg/day divided every 12 hours. For infants <1 month, loading: 10-15 mcg/kg, maintenance: 4-6 mcg/kg/day. For children 1-24 months, loading: 15-20 mcg/kg, maintenance: 5-8 mcg/kg/day. For children >2 years, loading: 10-15 mcg/kg, maintenance: 3-5 mcg/kg/day.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
None Documented
None Documented
Terminal elimination half-life in neonates is 35-70 hours, infants 18-30 hours, children 12-30 hours, and adults 36-48 hours; prolonged in renal impairment and hypothyroidism.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Renal excretion accounts for 50-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 30-40%, primarily as metabolites; enterohepatic recirculation occurs.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Category A/B
Category C
Cardiac Glycoside
Cardiac Glycoside